LoL. ........keep knawing on shoe leather. Refuses to face his own stupidity head on. What a shame. You reallY should look into high risk starts before he buYs them
After all my DD i continue to buy and accumulate, KEEP_regrets every move he makes from the Subaru to the filet of fiskh...... Hind sight keep...... Read BEFORE you buy.
ACT is moving forward with a name change but old habits die hard. The problem with informal communication from a company during the early stages of FDA trials is it leaves room for conjecture. The cataract surgery, which was never mentioned by the company could be highly relevant to the efficacy results as the referenced study suggests. The bottom line is ACT is still in the process of completing Phase I safety trials. The results should be encouraging enough based on the safety profile to support a large, well designed Phase II study. That, of course, is the purpose of a safety trial so, in that regard, I think ACT's results will be a success. But, as I mentioned earlier, the market has focused on efficacy and expectations are high. Maybe, too high.